Will plant-made biopharmaceuticals play a role in the fight against COVID-19?

Rosales‐Mendoza, Sergio

doi:10.1080/14712598.2020.1752177

Cited by 51 publications

(46 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plant molecular farming approaches offer scalability: while in fermentation-based platform, every scale-up step needs to be carefully verified-in molecular farming, each plant is a bioreactor. The more plants are grown, the more product is made; scale-up does not change the upstream production processes 82,85 . Other positive attributes of the molecular farming platform are the low manufacturing costs, the inability of human pathogens to replicate in plant cells (hence safety), and relatively non-sophisticated infrastructure that could be implemented worldwide also in low-resource countries.…”

Section: Review Article | Focusmentioning

confidence: 99%

COVID-19 vaccine development and a potential nanomaterial path forward

et al. 2020

View full text Add to dashboard Cite

, a novel coronavirus (nCoV or SARS-CoV-2) belonging to the betacoronavirus family emerged 1,2. All human betacoronaviruses are unique from one another, however, they do share a certain degree of genetic and structural homology. SARS-CoV-2 genome sequence homology with SARS-CoV and MERS-CoV is 77% and 50%, respectively 3. In contrast to the relatively smaller outbreaks of SARS-CoV in 2002 and MERS-CoV in 2012, SARS-CoV-2 is exhibiting an unprecedented scale of infection, resulting in a global pandemic declaration of Coronavirus Infectious Disease (COVID-19) on 11 March 2020 by the World Health Organization (WHO). On 1 June 2020, the World Health Organization reported >6 million confirmed cases and 371 thousand deaths globally. Of note, during the 1918 influenza pandemic, more death was observed in the second phase of outbreak 4. Similar to influenza, COVID-19 harbours the potential to become a seasonal disease 5. The high infection rate, long incubation period, along with mild-to-moderate symptoms experienced by many, make COVID-19 a troubling disease. A vaccine is crucial, in particular because data indicate asymptomatic transmission of COVID-19 6-8. More than 10 years ago, scientists predicted the pandemic potential of the coronaviruses 9. And for the past 30 years, a once-per-decade novel coronavirus has pushed our public health system to the limit, with SARS-CoV-2 being the most severe. Despite the repeated warnings and discussion, the world was not prepared for this pandemic. The rapid development, distribution and administration of a vaccine to the global population is the most effective approach to quell this pandemic and the only one that will lead to a complete lifting of restrictions. Challenges include the vaccine design itself, but also its manufacture and global distribution; cold chain requirements present logistical and fiscal barriers to the availability of important, life-saving vaccines in resource-poor areas of the world. Innovating vaccine delivery platforms and devices to break cold chain limitations are therefore an efficient solution to safeguard potent vaccination for both wealthy and lower-income countries.

show abstract

Section: Review Article | Focusmentioning

confidence: 99%

COVID-19 vaccine development and a potential nanomaterial path forward

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This infection has created a massive demand for diagnostic reagents, vaccines, and therapeutic development. Given the speed advantages, and proven viability of the plant production platform, the transient expression system in particular could be employed to produce recombinant proteins at high levels to meet the sudden demand for production of viral antigens or antiviral proteins that could be used as research reagents, emergency vaccines (SARS-CoV-2 subunit and virus-like particle vaccines), or other biopharmaceuticals to fight against COVID-19 [25,124]. The neutralizing monoclonal antibodies against SARS-CoV-2 could also be produced in plants with minimal investment, which could be used for passive immunotherapy [125].…”

Section: Strategies Used For Recombinant Protein Production In Plantsmentioning

confidence: 99%

Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production

Shanmugaraj

Bulaon

Phoolcharoen

2020

Plants

160

166

View full text Add to dashboard Cite

The demand for recombinant proteins in terms of quality, quantity, and diversity is increasing steadily, which is attracting global attention for the development of new recombinant protein production technologies and the engineering of conventional established expression systems based on bacteria or mammalian cell cultures. Since the advancements of plant genetic engineering in the 1980s, plants have been used for the production of economically valuable, biologically active non-native proteins or biopharmaceuticals, the concept termed as plant molecular farming (PMF). PMF is considered as a cost-effective technology that has grown and advanced tremendously over the past two decades. The development and improvement of the transient expression system has significantly reduced the protein production timeline and greatly improved the protein yield in plants. The major factors that drive the plant-based platform towards potential competitors for the conventional expression system are cost-effectiveness, scalability, flexibility, versatility, and robustness of the system. Many biopharmaceuticals including recombinant vaccine antigens, monoclonal antibodies, and other commercially viable proteins are produced in plants, some of which are in the pre-clinical and clinical pipeline. In this review, we consider the importance of a plant- based production system for recombinant protein production, and its potential to produce biopharmaceuticals is discussed.

show abstract

“…However, oral vaccines could be possibly developed by plant-based vaccine technology, using plant cell as an antigen delivery agent and may prove an attractive approach in terms of cost, induction of mucosal immunity and easy delivery. 80,81 Live viral vector-based vaccines These include the vaccines that are based on chemically weakened viruses, which are exploited for carrying antigens or pathogens of interest for inducing the immune response. They induce potent immunity including cell-mediated immunity (https://www.who.int/biologicals/publications/trs/areas/ vaccines/typhus/viral_vectors/en/).…”

Section: Nucleic Acid-based Vaccinesmentioning

confidence: 99%

COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines

Yatoo

Hamid

Parray

et al. 2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The COVID-19 pandemic caused by SARS-CoV-2 has spread rapidly. To date, countries have relied on the prevention of the disease through isolation, quarantine, and clinical care of affected individuals. However, studies on the roles of asymptomatic and mildly infected subjects in disease transmission, use of antiviral drugs, and vaccination of the general population will be very important for mitigating the effects of the eventual return of this pandemic. Initial investigations are ongoing to evaluate antigenic structures of SARS-CoV-2 and the immunogenicity of vaccine candidates. There also is a need to comprehensively compile the details of previous studies on SARS-related vaccines that can be extrapolated to identify potent vaccine targets for developing COVID-19 vaccines. This review aims to analyze previous studies, current status, and future possibilities for producing SARS-CoV-2 vaccines.

show abstract

Will plant-made biopharmaceuticals play a role in the fight against COVID-19?

Cited by 51 publications

References 20 publications

COVID-19 vaccine development and a potential nanomaterial path forward

COVID-19 vaccine development and a potential nanomaterial path forward

Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production

COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines

Contact Info

Product

Resources

About